Takeaway
There is evidence that the innate immune system recognizes structurally abnormal prion protein (PrPSc), and that targeting the interferon (IFN) pathway may limit disease progression.
Why this matters
Elucidation of the interactions between prions and the immune system may facilitate the development of new therapeutic strategies.